 ATLANTA--BUSINESS WIRE--Virios Therapeutics, Inc. Nasdaq: VIRI, a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today dosing of the first patient in its Phase 2b clinical trial, referred to as FORTRESS Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1, evaluating IMC-1 in patients with fibromyalgia. IMC-1 is a novel, proprietary, 